Methods and compositions for treating solid and liquid b-cell malignancies

The Multi-Antigen T-Cell Hybridizers (MATCH) platform addresses the toxicity issues of current T-cell therapies by separating cancer and T-cell engager doses, reducing cytokine release and enhancing tumor cell killing in B-cell malignancies, offering a safer and more effective treatment.

WO2026136390A1PCT designated stage Publication Date: 2026-06-25UNIV OF UTAH RES FOUND +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
UNIV OF UTAH RES FOUND
Filing Date
2025-12-16
Publication Date
2026-06-25

AI Technical Summary

Technical Problem

Current T-cell immunotherapies for B-cell malignancies, such as CAR-T cell therapies and bispecific antibodies, are limited by significant side-effects like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which restrict their broad utilization due to toxicity and relapse issues.

Method used

A two-component immunotherapy platform using morpholino oligonucleotide-linked conjugates, named Multi-Antigen T-Cell Hybridizers (MATCH), allows for separate dosing of cancer cell and T-cell engagers, inducing apoptosis through mechanisms like perforin pore formation and granzyme-mediated pathways, reducing systemic cytokine release and enhancing tumor cell killing.

Benefits of technology

The MATCH platform significantly reduces CRS and ICANS while maintaining anti-tumor efficacy by optimizing B-cell and T-cell engager doses, providing a safer and more effective treatment for both solid and liquid B-cell tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2025059886_25062026_PF_FP_ABST
    Figure US2025059886_25062026_PF_FP_ABST
Patent Text Reader

Abstract

Described herein are methods and compositions for treating solid or liquid B-cell malignancies using a two-component platform based on morpholino oligonucleotide-linked conjugates to target B-cells and effector cells. The methods described herein may involve two distinct dosing approaches tailored to the type of B-cell malignancy being treated. In some embodiments, solid B-cell tumors are treated using a premixed assembly dosing regimen. In some embodiments, liquid B-cell tumors are treated using a consecutive dosing regimen.
Need to check novelty before this filing date? Find Prior Art